Contents
Issue 124 • November 2022
In association with
In association with
Comment
Sandoz spin-off continues Novartis’ focus on innovation
High risk, high reward – the future of CAR-T therapy in CLL
bluebird bio bags successive landmark FDA approvals for gene therapies
Covid-19 vaccine companies boosted with over 80% revenue growth
Urgent need to update Canada’s breast cancer screening guidelines
The epidemiology of RSV changed in UK children during the pandemic
In Depth
Medicine in outer space: drug development, manufacturing, and beyond
Oncology therapies dominate the orphan drug landscape
How environmental factors could influence disease and drugs
Joining the dots: How gene regulatory network tools are unearthing drugs
Inflation drives pharma manufacturing focus on sustainability
Decentralised regulation: What do remote assessments mean for sponsors?
CMO Moves: Regulatory catalysts for drug manufacturing-October
Comment
Sandoz spin-off continues Novartis’s focus on innovation